Clinicians treating patients with T2D need to know how to choose and optimally use incretin therapies that have activity against common comorbidities in T2D, including obesity and CVD. Over the past decade there have been several new classes of drugs …
Recent data has led to a debate of the most effective maintenance strategy for advanced OC. Emerging data utilizing novel approaches to maintenance both further complicates the debate and sheds new light on novel effective strategies for maintenance therapy for …
Patients with narcolepsy experience excessive daytime sleepiness, cataplexy, disrupted night-time sleep, hypnagogic hallucinations, and sleep paralysis. Patients frequently cope with these symptoms for years, at great expense to their quality of life, and often have to see multiple specialists before …
Mycophenolate is the most common immunosuppressant used for preventing organ rejection in transplant recipients and is frequently employed in other disciplines, such as rheumatology. In response to the discovery of fetal teratogenicity associated with mycophenolate use during pregnancy, the FDA …
Narcolepsy is a chronic sleep disorder that affects approximately one in 2,000 individuals. The patient’s diagnostic journey is often long and complex, and narcolepsy frequently remains undiagnosed or is misdiagnosed as other conditions, including depression, schizophrenia, insomnia, or obstructive sleep …
The emerging class of amyloid-targeting therapies (ATTs) are at the forefront of innovative approaches that promise to alter the course of Alzheimer’s disease (AD). However, the translation of these scientific advancements into clinical practice necessitates a well-informed clinical workforce adept …
Alzheimer’s disease (AD) presents a growing challenge in contemporary health care, with escalating prevalence and a significant burden imposed on patients, families, and health care systems globally. Early and accurate diagnosis of AD is essential for effective support and treatment. …
The Food and Drug Administration (FDA) recently approved immune checkpoint inhibitors (ICIs) for patients with advanced or recurrent endometrial cancer (EC) who did not respond to first-line treatment with chemotherapy. This led to several new trials of emerging therapies, including …